A Rutgers-led study published in Annals of Internal Medicine links GLP-1 drugs including Ozempic and Wegovy to a modest increase in ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The lead author put the increase at roughly three to four additional cases per 10,000 patients over 18 months, and says the data does not establish causation.
Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.
A KFF Health News investigation details adverse event reports tied to BPC-157 while the FDA sits on an advisory panel's July recommendation to ease access to six unapproved peptides. Nevada regulators fined four parties over a 2025 incident in which two women were intubated, but never determined the cause.
A 12-month study at a single U.S. cardiology clinic reports GLP-1 receptor agonist use rising from 7.8% to 92.2% under a nurse practitioner-led program, alongside improvements in weight, symptom scores and walk distance. The pre-post design used each patient's own prior year as the comparator, with no separate control group.
Two new papers on the mitochondrial peptide MOTS-c land in the same week, one reporting protection of retinal blood vessels in diabetic mice, the other warning that the peptide's effects reverse depending on context. Human abundance data remain inconsistent and no clinical trial has tested supplementation.
A GlobeNewswire release says a review of supplier Kylo Peptides sets a documentation benchmark for the research peptide market, citing lot-matched COAs and four independent testing labs. It also cites a 2026 analysis in which fewer than six in ten sampled research peptides met both purity and label-accuracy thresholds.
Semaglutide has randomized trial data behind it, which is more than most compounds sold under the word peptide. Here is what four recent studies reported, and the sizable gaps they leave open.
A preprint survey of 829 GLP-1 receptor agonist users reports reduced alcohol use in 72 percent of drinkers and near-universal side effects that two-thirds said barely affected life satisfaction. It is self-reported, uncontrolled and self-selected, which is exactly how far the findings go.
A study of more than 47,000 UK surgical patients found those on GLP-1 drugs were 11 times more likely to regurgitate or aspirate under general anesthetic, though the authors say the link is not necessarily causal. Anesthetists say patients are hiding their use, including unapproved peptides bought at the gym, and that the evidence base for pausing the drugs before surgery barely exists.
A September 2026 preprint identified 1,039 documented BPC-157 users and a roughly 33-fold rise in new users since 2020, while the named human studies behind the peptide involve 16 people and two people. Here is what the research actually reports, and the large amount it does not.
Sports medicine physician Jordan D. Metzl argues that semaglutide's randomized trial data should not be confused with the evidence behind BPC-157, TB-500, CJC-1295 and ipamorelin. He says he wants more peptide research, not fewer questions about it.
A September 2026 preprint analyzing 15 million medical records found a roughly 33-fold rise in documented BPC-157 users between 2020 and 2026, with pain relief the dominant reason given. Human evidence remains limited to preclinical work and very small studies, and an FDA advisory panel's 8-6 compounding vote did not change that.
A study presented at the EADV Congress 2026 found nail detachment reported in 39% of GLP-1 users versus 9% of non-users, with the gap holding regardless of weight lost. The authors stress the finding is an association, not proof that the medications cause it.
A Yahoo Health feature reports that peptide therapy marketed for menopause symptoms has no supporting clinical evidence, with two physicians saying the research simply is not there. The exception they name is GLP-1 drugs, where one study found postmenopausal women on hormone therapy lost 35 percent more weight on tirzepatide.
Wired had four "research use only" peptide vials bought from a Brooklyn bodega tested, and none contained the active ingredient on the label. The samples showed low heavy metals and endotoxins, but what was actually in them is still unknown.
A French nationwide cohort of 19,092 pregnancies found no increased risk of major congenital malformations with first-trimester exposure to second-line glucose-lowering drugs, compared with insulin alone. Sensitivity analyses suggested a possible small increase in cardiac malformations after GLP-1 receptor agonist and sulfonylurea exposure.
Two large observational studies touch tirzepatide from very different angles: a three-year veterans cohort on cardiovascular events after stopping GLP-1 therapy, and a matched cohort on oral and periodontal outcomes. Neither demonstrates cause, and one does not isolate tirzepatide at all.
An RTE report examines the social media boom in self-administered peptide injections and the near-total absence of human trials behind the claims. An endocrinologist calls the biochemistry sound but says it is far too early to use these substances in people.
A three-year analysis of more than 333,000 U.S. veterans with type 2 diabetes found that stopping GLP-1 therapy was associated with higher risk of heart attack, stroke and death, reaching 22% after two years off. Restarting the medication restored some of the protection, but not all of it.
A new study in Childhood Obesity reports that 16.8% of patients ages 10 to 17 were diagnosed with a nutritional deficiency within a year of starting a GLP-1 medication, with vitamin D deficiency most common at 12.4%. Only 5% received nutritional counseling in the first 30 days.
A systematic review pooling all 13 phase 2 and 3 trials of orforglipron and danuglipron reports broadly comparable efficacy but sharply different tolerability and hepatic safety. The preprint argues dosing and discontinuation, not pharmacodynamics, decided which oral GLP-1 program survived.
A network meta-analysis in Diabetes, Obesity & Metabolism reported that semaglutide carried the highest NAION risk among GLP-1 receptor agonists, followed by liraglutide. The mechanistic half of the paper is entirely computational, and the authors present the findings as a guide for future research rather than proof of causation.
An FDA advisory committee voted in July to recommend MOTS-c for the 503A Bulks List, but the vote carries no legal effect and the rulemaking has not started. None of the available coverage names a single human trial of the mitochondrial-derived peptide, its size or its result.
TB-500 is a seven-amino-acid fragment of thymosin beta-4, and FDA states the two are different substances. A review of the evidence finds a cell migration hypothesis, one unhelpful 2024 lab result, and no published human studies at all.
A review in World Journal of Transplantation looks at whether GLP-1 and GLP-1/GIP receptor agonists could help manage obesity in liver transplant recipients. The authors say long-term safety, dosing and outcomes remain insufficiently studied in this population.
Semaglutide research now spans mouse lifespan experiments, a genetic link to male-pattern hair loss, and 400,000 Reddit posts mined for unreported symptoms. Here is what each of those studies actually reported, and what none of them established.
A Nature Health study analyzed 400,000 Reddit posts from GLP-1 users and surfaced fatigue, menstrual irregularities, chills and hot flashes alongside the familiar gastrointestinal complaints. The researchers established a link, not a cause, and clinicians Allure spoke with say rapid weight loss and hormone shifts complicate the picture.
A prospective real-world study across 14 sites in Taiwan reported mean losses of 4.4 kg in body weight and 1.9 kg/m2 in BMI at week 26 among 41 adolescents receiving liraglutide. Adverse events were described as mild and no one stopped treatment for intolerance, but the study had no control group and only 41 participants.
A 45-member expert panel in World Psychiatry reached 91.7% average consensus on recommendations for GLP-1 receptor agonist use in people with eating disorders, including pre-prescription screening. The panel says the drugs should generally be avoided in active anorexia nervosa and restrictive bulimia nervosa, and that trials in binge eating disorder are still missing.
A Nerdbot review scores research-peptide supplier Cellugenix 9.5 out of 10, citing a public batch certificate library, 99%+ documented purity, and testing through a named independent lab. Every figure in it comes from the company's own site and documentation, and no samples were independently assayed for the review.
A meta-analysis of 41 randomized trials in Diabetes, Obesity & Metabolism reported a 45% reduction in urine albumin-to-creatinine ratio with SGLT-2 or RAS inhibitors in type 1 diabetes, with no change in filtration rate. The same pooled analysis found a nearly doubled relative risk of diabetic ketoacidosis.
A University of Pennsylvania team used large language models to analyze more than 400,000 Reddit posts about semaglutide and tirzepatide, flagging reproductive and body temperature symptoms as underrepresented in trial data. The researchers stress the findings are associations in online discussion, not evidence the drugs caused anything.
Researchers report that a self-propelled silica nanomotor carrying a rapeseed-derived DPP-IV inhibitory peptide and liraglutide improved glucose tolerance in diabetic mice. The work is entirely preclinical, with cell culture and a single rodent model behind every figure.
An NYU Langone genetic analysis reports an additional 7 percent hair loss risk linked to GLP-1 receptor activity in men with inherited male-pattern baldness. The study used genetic databases rather than patients on the drugs, and could only examine the question in men.
A Mendelian randomization study in Heart & Lung reports that genetically proxied GLP-1 receptor pathway activation was associated with lower heart failure risk, with reduced MMP-1 accounting for 21 to 28 percent of the effect. The association was modest and borderline by conventional standards, and the authors call MMP-1 only a partial mediator.
An umbrella review of 18 meta-analyses found adjunctive GLP-1 receptor agonist therapy in type 1 diabetes was associated with a 0.23 percent HbA1c reduction and 3.93 kg weight loss, with nausea and vomiting risks roughly tripled. The authors say the results do not support routine use, and note that 19.6 percent primary-study overlap makes the evidence base look larger than it is.
Dermatologists and longevity researchers are urging patients not to inject GHK-Cu, the copper peptide long sold in serums, because no published human study covers the injectable form. An FDA advisory panel is scheduled to review the evidence in February.
A Griffith University analysis of nearly 15,000 Swedish patients found semaglutide use was associated with a 21 percent lower risk of psychiatric hospitalization in people with bipolar disorder. Liraglutide and dulaglutide showed no such association, and the researchers are calling for a randomized trial.
Bowery Clinic says it has expanded its physician-guided Selank program and published an educational overview of the synthetic peptide. The human trials it cites involve about 60 patients each, and Selank is not FDA-approved for anything in the United States.
A review in Hormone and Metabolic Research surveys GLP-1 and melanocortin-4 receptor agonists, including the dual and triple agents now dominating the obesity pipeline. It carries no new trial data, and the abstract states no outcome figures.
The FDA has approved Mounjaro to reduce cardiovascular risk in high-risk people with type 2 diabetes, based on a 13,000-person head-to-head trial against Trulicity. Major cardiovascular events occurred in 12.2% of Mounjaro participants versus 13.1% on the comparator, and cardiologists caution the studied population was unusually high risk.
Synthesis Peptides says it now pulls eight vials at random from every production lot for HPLC and LC-MS testing, with batch-specific Certificates of Analysis published publicly. The release names no purity threshold and does not identify the independent testing lab.
Karnataka Food Safety and Drug Administration officials shut down an invite-only Bengaluru biohacking event that advertised "peptide tasting" ahead of its August 29 date. The report names no substance, which is part of what made the shutdown so quick.
A Hartford HealthCare interview with Joe Li, DO, separates peptide medications with clinical evidence behind them from the injections sold online for recovery and anti-aging. The piece names BPC-157, ipamorelin and CJC-1295 as compounds whose marketed uses are not backed by human research.
A UCLA Health review of 565 studies on BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu found more than two-thirds were animal-only and essentially none showed significant clinical benefit for musculoskeletal conditions. The authors also flag a halted MK-677 trial, financial conflicts in a major BPC-157 study, and contamination risks in unregulated products.
A Hartford Hospital explainer argues that "peptide therapy" now covers everything from insulin to unstudied injections sold online, with very different evidence behind each. Physician Joe Li, DO, says the wellness-clinic peptides like BPC-157, ipamorelin and CJC-1295 have mostly been researched in labs and animals rather than people.
The Karnataka FDA says a "Peptide Party" planned for Koramangala on August 29 was cancelled after the department demanded composition, dosage, manufacturer and regulatory-status details from organizers Upsurge Labs LLP. The notice also sought scientific evidence for claims spanning weight loss, muscle growth, anti-aging, diabetes and athletic performance.
A ten-vendor audit scored peptide suppliers on certificates, named labs, lot matching and price per milligram, and found the expensive end of the market is not the documented end.
A matched retrospective cohort study in the Clinical Journal of the American Society of Nephrology reports that GLP-1RA use was independently associated with lower hospitalization and mortality rates among patients starting in-center hemodialysis. The effect sizes are modest, the design cannot establish cause, and the authors say so.
A signal-detection analysis indexed by Europe PMC reports that all five GLP-1 receptor agonists it examined met conventional signal criteria for impaired gastric emptying in FAERS. The authors state the work is descriptive and hypothesis-generating and makes no claim about clinical risk.
A signal-detection analysis of the FDA Adverse Event Reporting System reports that all nine marketed GLP-1 receptor agonist products met conventional criteria for a disproportionate reporting signal for impaired gastric emptying. The authors state the analysis is descriptive and hypothesis-generating and makes no claim about clinical risk.
Doctors in Victoria told the ABC they suspect a contaminated batch of counterfeit peptides is behind seven hospitalizations for acute liver toxicity. The TGA says the retatrutide sold online is not the product Eli Lilly is testing in trials.
A Houston compounding pharmacy is recalling one lot of injectable glutathione after testing found elevated bacterial endotoxin levels, the FDA said. It is the second Texas pharmacy in weeks to pull injectable product over the same problem.
